Technical CommentsCancer

Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”

See allHide authors and affiliations

Science Translational Medicine  17 Jul 2019:
Vol. 11, Issue 501, eaau0416
DOI: 10.1126/scitranslmed.aau0416

Article Information

vol. 11 no. 501

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 1, 2018
  • Accepted for publication May 9, 2019
  • .

Author Information

  1. Danilo Perrotti1,2,*,,
  2. Anupriya Agarwal3,*,
  3. Claire M. Lucas4,*,
  4. Goutham Narla5,*,
  5. Paolo Neviani6,*,
  6. Maria D. Odero7,*,
  7. Peter P. Ruvolo8,* and
  8. Nicole M. Verrills9,*
  1. 1University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  2. 2Department of Haematology, Imperial College London, London W12 0HS, UK.
  3. 3Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
  4. 4University of Chester Medical School, Chester CH2 1BR, UK.
  5. 5Department of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  6. 6Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.
  7. 7University of Navarra, Pamplona 31009, Spain.
  8. 8Department of Leukemia, MD Anderson Cancer Center, Houston, 77054 TX, USA.
  9. 9School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.
  1. Corresponding author. Email: dperrotti{at}som.umaryland.edu
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: July 2019 to October 2019

AbstractFullPdf
Jul 20192633222308
Aug 20195315186
Sep 2019237443
Oct 201982812

Navigate This Article